Seocalcitol - CAS 134404-52-7
Catalog number: 134404-52-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Seocalcitol is a vitamin D receptor (VDR) agonist. Seocalcitol exhibits anti-tumor and anti-proliferative activity with reduced hypercalcemic effects
White to off-white solid
EB 1089; CB1089; LMST03020449; CB-1089; EB-1089; EB1.
Canonical SMILES:
Current Developer:
Cougar Biotechnology, Inc
1.The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
Kim JS1, Roberts JM, Bingman WE 3rd, Shao L, Wang J, Ittmann MM, Weigel NL. Endocrinology. 2014 Sep;155(9):3262-73. doi: 10.1210/en.2013-2019. Epub 2014 Jun 13.
A number of preclinical studies have shown that the activation of the vitamin D receptor (VDR) reduces prostate cancer (PCa) cell and tumor growth. The majority of human PCas express a transmembrane protease serine 2 (TMPRSS2):erythroblast transformation-specific (ETS) fusion gene, but most preclinical studies have been performed in PCa models lacking TMPRSS2:ETS in part due to the limited availability of model systems expressing endogenous TMPRSS2:ETS. The level of the active metabolite of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25D), is controlled in part by VDR-dependent induction of cytochrome P450, family 24, subfamily 1, polypeptide1 (CYP24A1), which metabolizes 1,25D to an inactive form. Because ETS factors can cooperate with VDR to induce rat CYP24A1, we tested whether TMPRSS2:ETS would cause aberrant induction of human CYP24A1 limiting the activity of VDR. In TMPRSS2:ETS positive VCaP cells, depletion of TMPRSS2:ETS substantially reduced 1,25D-mediated CYP24A1 induction.
2.VDR hypermethylation and HIV-induced T cell loss.
Chandel N1, Husain M, Goel H, Salhan D, Lan X, Malhotra A, McGowan J, Singhal PC. J Leukoc Biol. 2013 Apr;93(4):623-31. doi: 10.1189/jlb.0812383. Epub 2013 Feb 6.
Epigenetics contributes to the development of variety of diseases by modulation of gene expression. We evaluated the effect of HIV-induced VDR methylation on loss of TCs. HIV/TC displayed enhanced VDR-CpG methylation and increased expression of Dnmt3b but attenuated expression of VDR. A demethylating agent, AZA, inhibited this effect of HIV. HIV/TC also displayed the activation of the RAS, which was reversed by EB (a VDA). Further, HIV/TCs displayed enhanced generation of ROS and induction of DSBs but attenuated DNA repair response. However, in the presence of AZA, EB, LOS (a RAS blocker), Cat, and tempol (free radical scavengers), HIV-induced TC ROS generation and induction of DSBs were attenuated but associated with enhanced DNA repair. Additionally, AZA, EB, and LOS provided protection against HIV-induced TC apoptosis. These findings suggested that HIV-induced TC apoptosis was mediated through ROS generation in response to HIV-induced VDR methylation and associated activation of the RAS.
3.Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.
Pickholtz I1, Saadyan S2, Keshet GI3, Wang VS4, Cohen R2, Bouwman P5, Jonkers J5, Byers SW6, Papa MZ7, Yarden RI8. Oncotarget. 2014 Dec 15;5(23):11827-46.
Carriers of germline mutations in the BRCA1 gene have a significant increased lifetime risk for being diagnosed with breast cancer. The incomplete penetrance of BRCA1 suggests that environmental and/or genetic factors modify the risk and incidence among mutation carriers. Nutrition and particular micronutrients play a central role in modifying the phenotypic expression of a given genotype by regulating chromatin structure and gene expression. The active form of vitamin D, 1α,25-dihydroxyvitamin D3, is a potent inhibitor of breast cancer growth. Here we report that two non-calcemic analogues of 1α,25-dihydroxyvitamin D3, seocalcitol (EB1089) and QW-1624F2-2, collaborate with BRCA1 in mediating growth inhibition of breast cancer cells and breast cancer stem-like cells. EB1089 induces a G1/S phase growth arrest that coincides with induction of p21waf1 expression only in BRCA1-expressing cells. A complete knockdown of BRCA1 or p21waf1 renders the cells unresponsive to EB1089.
4.Vitamin D analog EB1089 induces apoptosis in a subpopulation of SGC-7901 gastric cancer cells through a mitochondrial-dependent apoptotic pathway.
Wang W1, Zhao CH, Zhang N, Wang J. Nutr Cancer. 2013;65(7):1067-75. doi: 10.1080/01635581.2013.811273. Epub 2013 Oct 7.
Gastric cancer is the second leading cause of cancer death worldwide. Cancer stem-like side population (SP) cells may be important factors that hinder efficacy of chemopreventative and chemotherapeutic approaches in gastric cancer. EB1089 is an antitumor agent that has been used in many cancers; however, no reports to date have determined the effects of EB1089 in gastric cancer. In our study, SP and main population (MP) cells were isolated from 4 gastric cancer cell lines in different stages of differentiation by flow cytometry (FCM) and confirmed by reverse transcription polymerase chain reaction (RT-PCR) and Western blot. EB1089 decreased the proliferation, increased apoptosis, and induced mitochondrial damage in the SP cells isolated from 1 cell type (SGC-7901), but not MP cells, through increased Bax and decreased Bcl-2 and Bcl-xL protein expression. This protein expression pattern induced the activation of caspase-3 and caspase-9. The effects of EB1089 on SGC-7901 SP cells were blocked by treating cells with vitamin D receceptor (VDR) siRNA or butin (an inhibitor of the mitochondrial apoptosis pathway).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related VD/VDR Products

CAS 112827-99-3 24R-Calcipotriol

(CAS: 112827-99-3)

24R-Calcipotriol is an impurity of Calcipotriol, which is a ligand of VDR-like receptors.

CAS 60133-18-8 Ercalcitriol

(CAS: 60133-18-8)

Ercalcitriol is a active metabolite of vitamin D2. It exhibits equipotent antirachitic activity in rats as calcitriol.

CAS 54573-75-0 Doxercalciferol

(CAS: 54573-75-0)

Doxercalciferol (Hectorol; 1.alpha.-Hydroxyvitamin D2) is a synthetic analog of vitamin D; is a Vitamin D2 analog that acts as a vitamin D receptor activator (V...

CAS 82266-85-1 Impurity C of Alfacalcidol

Impurity C of Alfacalcidol
(CAS: 82266-85-1)

Impurity C of Alfacalcidol is impurity of Alfacalcidol, which is a non-selective VDR activator medication. Alfacalcidol improves mechanical bone strength and bo...

CAS 57333-96-7 Tacalcitol

(CAS: 57333-96-7)

Tacalcitol promotes normal bone development by regulating calcium and modulates immunological and inflammatory processes. lt induces nerve growth factor product...

CAS 41294-56-8 Alfacalcidol

(CAS: 41294-56-8)

A synthetic analog of Calcitiol (the hormonal form of vitamin D3), which shows identical potency with respect to stimulation of intestinal calcium absorption an...

CAS 199798-84-0 BXL 628

BXL 628
(CAS: 199798-84-0)

BXL 628 is a vitamin D3 analogue that competes with vitamin D receptor (VDR) for inhibition of prostate cell growth and RhoA/Rho-kinase signaling, a calcium sen...

CAS 112828-09-8 (24R)-MC 976

(24R)-MC 976
(CAS: 112828-09-8)

(24R)-MC 976 is a Vitamin D3 derivative.

Chemical Structure

CAS 134404-52-7 Seocalcitol

Quick Inquiry

Verification code

Featured Items